The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma.
Georgalas
Ilias
I
Koutsandrea
Chrysanthi
C
Papaconstantinou
Dimitris
D
Petrou
Petros
P
Ladas
Ioannis
I
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000867:Anterior Chamber / Q000187:drug effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D014129:Trabecular Meshwork / Q000601:surgery*; D014130:Trabeculectomy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab